Literature DB >> 12450694

Safety and efficacy of E coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori.

Stavros Sougioultzis1, Cynthia K Lee, Mazen Alsahli, Subhas Banerjee, Michel Cadoz, Robert Schrader, Bruno Guy, Philip Bedford, Thomas P Monath, Ciaran P Kelly, Pierre Michetti.   

Abstract

Low dose E. coli heat-labile enterotoxin (LT), delivered orally or enterically, has been used as an adjuvant for Helicobacter pylori (H. pylori) urease in healthy adults. In this study we aim to test the safety and adjuvant efficacy of LT delivered rectally together with recombinant H. pylori urease. Eighteen healthy adults without present or past H. pylori infection were enrolled in a double blind, randomized, ascending dose study to receive either urease (60 mg), or urease (60 mg) + LT (5 or 25 microg). The immunization preparation was administered per rectum on days 0, 14 and 28. Serum, stool and saliva anti-urease and anti-LT IgG and IgA antibodies (Abs) were measured and urease-specific and LT-specific antigen secreting cells (ASCs) were counted in peripheral blood at baseline and 7 (ASC counts) or 14 days (antibody levels) after each dosing. Peripheral blood lymphoproliferation assays were also performed at baseline and at the end of the study. Rectally delivered urease and LT were well tolerated. Among the 12 subjects assigned to urease+LT, 2 (16.7%) developed anti-urease IgG Abs, 1 (8.3%) developed anti-urease IgA Abs, and 3 (25%) showed urease-specific IgA(+) ASCs. Immune responses to LT were more vigorous, especially in subjects exposed to 5 microg LT. In the urease+ 5 microg LT group, anti-LT IgG and IgA Abs developed in 60 and 80% of the subjects, respectively, while LT-specific IgG(+) and IgA(+) ASCs were detected in all subjects. The magnitude of the anti-LT response was much higher than the response to urease. No IgA anti-urease or anti-LT Abs were detected in stool or saliva and lymphocyte proliferative responses to urease were unsatisfactory. In conclusion, rectal delivery of 5 microg LT is safe and induces vigorous systemic anti-LT immune responses. Further studies are needed to determine if LT can be an effective adjuvant for rectally delivered antigens.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12450694     DOI: 10.1016/s0264-410x(02)00467-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection.

Authors:  Nathalie Parez; Cynthia Fourgeux; Ali Mohamed; Catherine Dubuquoy; Mathieu Pillot; Axelle Dehee; Annie Charpilienne; Didier Poncet; Isabelle Schwartz-Cornil; Antoine Garbarg-Chenon
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  A strain-specific antigen in Japanese Helicobacter pylori recognized in sera of Japanese children.

Authors:  Masumi Okuda; Toshiro Sugiyama; Kenichi Fukunaga; Masaru Kondou; Eikichi Miyashiro; Teruko Nakazawa
Journal:  Clin Diagn Lab Immunol       Date:  2005-11

Review 3.  Identification of Helicobacter pylori and the evolution of an efficacious childhood vaccine to protect against gastritis and peptic ulcer disease.

Authors:  Thomas G Blanchard; Steven J Czinn
Journal:  Pediatr Res       Date:  2016-10-04       Impact factor: 3.756

Review 4.  Helicobacter pylori vaccination: is there a path to protection?

Authors:  Florian Anderl; Markus Gerhard
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 5.  Vaccinating against Helicobacter pylori in the developing world.

Authors:  Shamila Zawahir; Steven J Czinn; John G Nedrud; Thomas G Blanchard
Journal:  Gut Microbes       Date:  2013-11-06

6.  Construction of recombinant attenuated Salmonella typhimurium DNA vaccine expressing H pylori ureB and IL-2.

Authors:  Can Xu; Zhao-Shen Li; Yi-Qi Du; Yan-Fang Gong; Hua Yang; Bo Sun; Jing Jin
Journal:  World J Gastroenterol       Date:  2007-02-14       Impact factor: 5.742

Review 7.  Vaccinating against Helicobacter pylori infection.

Authors:  Steven J Czinn; Thomas Blanchard
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02-08       Impact factor: 46.802

8.  Mucosal adjuvant properties of mutant LT-IIa and LT-IIb enterotoxins that exhibit altered ganglioside-binding activities.

Authors:  Hesham F Nawar; Sergio Arce; Michael W Russell; Terry D Connell
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

9.  Recombinant herpesvirus glycoprotein G improves the protective immune response to Helicobacter pylori vaccination in a mouse model of disease.

Authors:  Louise Baker; Andre M L Chitas; Carol A Hartley; Mauricio J C Coppo; Paola K Vaz; Andrew Stent; James R Gilkerson; Joanne M Devlin; Alison L Every
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

10.  Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin.

Authors:  Nancy A Summerton; Richard W Welch; Laureano Bondoc; Huei-Hsiung Yang; Brett Pleune; Naryaswamy Ramachandran; Andrea M Harris; Desiree Bland; W James Jackson; Sukjoon Park; John D Clements; Gary S Nabors
Journal:  Vaccine       Date:  2009-11-06       Impact factor: 3.641

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.